APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biomolecule Software

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biomolecule Software Market Outlook and Growth Opportunities 2026

1 January 2026216 pages

Choose your research edition.

Industry ResearchBiomolecule Software Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Biomolecule Software Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Biomolecule Software Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biomolecule Software Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Biomolecule Software Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Biomolecule Software market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biomolecule Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biomolecule Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biomolecule Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biomolecule Software market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biomolecule Software market include Hamilton Thorne, Hermes Medical Solutions, Inc, INDICAL BIOSCIENCE, lexogen, Repligen, SCC SOFT COMPUTER, Oxford Instruments, Partek, Inc. and Stilla Technologies, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Biomolecule Software market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biomolecule Software and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biomolecule Software revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Biomolecule Software market.

Biomolecule Software Segment by Company

Hamilton Thorne

Hermes Medical Solutions, Inc

INDICAL BIOSCIENCE

lexogen

Repligen

SCC SOFT COMPUTER

Oxford Instruments

Partek, Inc.

Stilla Technologies

Vela Diagnostics

Vittoriobasurto

SCIEX

SoftGenetics, LLC.

Benchling

BioSistemika

CapitalBio Technology

cytena GmbH

Eppendorf SE

GenomSys

Mission Bio

Multid Analyses AB

PhenoSystems SA

Progenie Molecular

Biomolecule Software Segment by Type

Windows

Linux

MacOS

Biomolecule Software Segment by Application

Hospital

Clinic

Research Center

Biomolecule Software Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biomolecule Software status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Biomolecule Software key companies, revenue, market share, and recent developments.

3. To split the Biomolecule Software breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Biomolecule Software market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biomolecule Software significant trends, drivers, influence factors in global and regions.

6. To analyze Biomolecule Software competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biomolecule Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biomolecule Software and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biomolecule Software.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biomolecule Software industry.

Chapter 3: Detailed analysis of Biomolecule Software company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Biomolecule Software in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Biomolecule Software in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biomolecule Software Industry Trends Table 2. Biomolecule Software Industry Drivers Table 3. Biomolecule Software Industry Opportunities and Challenges Table 4. Biomolecule Software Industry Restraints Table 5. Global Biomolecule Software Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biomolecule Software Revenue Share by Company (2021-2026) Table 7. Global Biomolecule Software Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Biomolecule Software Key Company Manufacturing Base & Headquarters Table 9. Global Biomolecule Software Company, Product Type & Application Table 10. Global Biomolecule Software Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Biomolecule Software by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Windows Table 15. Significant Companies of Linux Table 16. Significant Companies of MacOS Table 17. Global Biomolecule Software Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Biomolecule Software Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Biomolecule Software Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Biomolecule Software Sales Value Share by Type (2021-2026) Table 21. Global Biomolecule Software Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Clinic Table 24. Significant Companies of Research Center Table 25. Global Biomolecule Software Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Biomolecule Software Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Biomolecule Software Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Biomolecule Software Sales Value Share by Application (2021-2026) Table 29. Global Biomolecule Software Sales Value Share by Application (2027-2032) Table 30. Global Biomolecule Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Biomolecule Software Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Biomolecule Software Sales Value Share by Region (2021-2026) Table 33. Global Biomolecule Software Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Biomolecule Software Sales Value Share by Region (2027-2032) Table 35. Global Biomolecule Software Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Biomolecule Software Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Biomolecule Software Sales Value Market Share by Country (2021-2026) Table 38. Global Biomolecule Software Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Biomolecule Software Sales Value Market Share by Country (2027-2032) Table 40. Hamilton Thorne Company Information Table 41. Hamilton Thorne Business Overview Table 42. Hamilton Thorne Biomolecule Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Hamilton Thorne Biomolecule Software Product Portfolio Table 44. Hamilton Thorne Recent Development Table 45. Hermes Medical Solutions, Inc Company Information Table 46. Hermes Medical Solutions, Inc Business Overview Table 47. Hermes Medical Solutions, Inc Biomolecule Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Hermes Medical Solutions, Inc Biomolecule Software Product Portfolio Table 49. Hermes Medical Solutions, Inc Recent Development Table 50. INDICAL BIOSCIENCE Company Information Table 51. INDICAL BIOSCIENCE Business Overview Table 52. INDICAL BIOSCIENCE Biomolecule Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. INDICAL BIOSCIENCE Biomolecule Software Product Portfolio Table 54. INDICAL BIOSCIENCE Recent Development Table 55. lexogen Company Information Table 56. lexogen Business Overview Table 57. lexogen Biomolecule Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. lexogen Biomolecule Software Product Portfolio Table 59. lexogen Recent Development Table 60. Repligen Company Information Table 61. Repligen Business Overview Table 62. Repligen Biomolecule Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Repligen Biomolecule Software Product Portfolio Table 64. Repligen Recent Development Table 65. SCC SOFT COMPUTER Company Information Table 66. SCC SOFT COMPUTER Business Overview Table 67. SCC SOFT COMPUTER Biomolecule Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. SCC SOFT COMPUTER Biomolecule Software Product Portfolio Table 69. SCC SOFT COMPUTER Recent Development Table 70. Oxford Instruments Company Information Table 71. Oxford Instruments Business Overview Table 72. Oxford Instruments Biomolecule Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Oxford Instruments Biomolecule Software Product Portfolio Table 74. Oxford Instruments Recent Development Table 75. Partek, Inc. Company Information Table 76. Partek, Inc. Business Overview Table 77. Partek, Inc. Biomolecule Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Partek, Inc. Biomolecule Software Product Portfolio Table 79. Partek, Inc. Recent Development Table 80. Stilla Technologies Company Information Table 81. Stilla Technologies Business Overview Table 82. Stilla Technologies Biomolecule Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Stilla Technologies Biomolecule Software Product Portfolio Table 84. Stilla Technologies Recent Development Table 85. Vela Diagnostics Company Information Table 86. Vela Diagnostics Business Overview Table 87. Vela Diagnostics Biomolecule Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Vela Diagnostics Biomolecule Software Product Portfolio Table 89. Vela Diagnostics Recent Development Table 90. Vittoriobasurto Company Information Table 91. Vittoriobasurto Business Overview Table 92. Vittoriobasurto Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Vittoriobasurto Biomolecule Software Product Portfolio Table 94. Vittoriobasurto Recent Development Table 95. SCIEX Company Information Table 96. SCIEX Business Overview Table 97. SCIEX Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. SCIEX Biomolecule Software Product Portfolio Table 99. SCIEX Recent Development Table 100. SoftGenetics, LLC. Company Information Table 101. SoftGenetics, LLC. Business Overview Table 102. SoftGenetics, LLC. Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. SoftGenetics, LLC. Biomolecule Software Product Portfolio Table 104. SoftGenetics, LLC. Recent Development Table 105. Benchling Company Information Table 106. Benchling Business Overview Table 107. Benchling Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Benchling Biomolecule Software Product Portfolio Table 109. Benchling Recent Development Table 110. BioSistemika Company Information Table 111. BioSistemika Business Overview Table 112. BioSistemika Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. BioSistemika Biomolecule Software Product Portfolio Table 114. BioSistemika Recent Development Table 115. CapitalBio Technology Company Information Table 116. CapitalBio Technology Business Overview Table 117. CapitalBio Technology Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. CapitalBio Technology Biomolecule Software Product Portfolio Table 119. CapitalBio Technology Recent Development Table 120. cytena GmbH Company Information Table 121. cytena GmbH Business Overview Table 122. cytena GmbH Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. cytena GmbH Biomolecule Software Product Portfolio Table 124. cytena GmbH Recent Development Table 125. Eppendorf SE Company Information Table 126. Eppendorf SE Business Overview Table 127. Eppendorf SE Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Eppendorf SE Biomolecule Software Product Portfolio Table 129. Eppendorf SE Recent Development Table 130. GenomSys Company Information Table 131. GenomSys Business Overview Table 132. GenomSys Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. GenomSys Biomolecule Software Product Portfolio Table 134. GenomSys Recent Development Table 135. Mission Bio Company Information Table 136. Mission Bio Business Overview Table 137. Mission Bio Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Mission Bio Biomolecule Software Product Portfolio Table 139. Mission Bio Recent Development Table 140. Multid Analyses AB Company Information Table 141. Multid Analyses AB Business Overview Table 142. Multid Analyses AB Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Multid Analyses AB Biomolecule Software Product Portfolio Table 144. Multid Analyses AB Recent Development Table 145. PhenoSystems SA Company Information Table 146. PhenoSystems SA Business Overview Table 147. PhenoSystems SA Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. PhenoSystems SA Biomolecule Software Product Portfolio Table 149. PhenoSystems SA Recent Development Table 150. Progenie Molecular Company Information Table 151. Progenie Molecular Business Overview Table 152. Progenie Molecular Biomolecule Software Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Progenie Molecular Biomolecule Software Product Portfolio Table 154. Progenie Molecular Recent Development Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Biomolecule Software Product Image Figure 2. Global Biomolecule Software Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biomolecule Software Market Size (2021-2032) & (US$ Million) Figure 4. Global Biomolecule Software Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Windows Image Figure 8. Linux Image Figure 9. MacOS Image Figure 10. Global Biomolecule Software Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Biomolecule Software Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Biomolecule Software Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Research Center Image Figure 16. Global Biomolecule Software Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Biomolecule Software Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Biomolecule Software Sales Value Share by Application (2021-2032) Figure 19. Global Biomolecule Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Biomolecule Software Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Biomolecule Software Sales Value (2021-2032) & (US$ Million) Figure 22. North America Biomolecule Software Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Biomolecule Software Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Biomolecule Software Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Biomolecule Software Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Biomolecule Software Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Biomolecule Software Sales Value (2021-2032) & (US$ Million) Figure 28. South America Biomolecule Software Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Biomolecule Software Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Biomolecule Software Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Biomolecule Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Biomolecule Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Biomolecule Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Windows
  • Linux
  • MacOS
Applications
  • Hospital
  • Clinic
  • Research Center
Companies covered
  • Hamilton Thorne
  • Hermes Medical Solutions, Inc
  • INDICAL BIOSCIENCE
  • lexogen
  • Repligen
  • SCC SOFT COMPUTER
  • Oxford Instruments
  • Partek, Inc.
  • Stilla Technologies
  • Vela Diagnostics
  • Vittoriobasurto
  • SCIEX
  • SoftGenetics, LLC.
  • Benchling
  • BioSistemika
  • CapitalBio Technology
  • cytena GmbH
  • Eppendorf SE
  • GenomSys
  • Mission Bio
  • Multid Analyses AB
  • PhenoSystems SA
  • Progenie Molecular

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biomolecule Software Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biomolecule Software Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Biomolecule Software Market Dynamics
  1. 2.1 Biomolecule Software Industry Trends
  2. 2.2 Biomolecule Software Industry Drivers
  3. 2.3 Biomolecule Software Industry Opportunities and Challenges
  4. 2.4 Biomolecule Software Industry Restraints
3 Biomolecule Software Market by Company
  1. 3.1 Global Biomolecule Software Company Revenue Ranking in 2025
  2. 3.2 Global Biomolecule Software Revenue by Company (2021-2026)
  3. 3.3 Global Biomolecule Software Company Ranking (2024-2026)
  4. 3.4 Global Biomolecule Software Company Manufacturing Base and Headquarters
  5. 3.5 Global Biomolecule Software Company Product Type and Application
  6. 3.6 Global Biomolecule Software Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Biomolecule Software Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Biomolecule Software Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Biomolecule Software Market by Type
  1. 4.1 Biomolecule Software Type Introduction
  2. 4.1.1 Windows
  3. 4.1.2 Linux
  4. 4.1.3 MacOS
  5. 4.2 Global Biomolecule Software Sales Value by Type
  6. 4.2.1 Global Biomolecule Software Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Biomolecule Software Sales Value by Type (2021-2032)
  8. 4.2.3 Global Biomolecule Software Sales Value Share by Type (2021-2032)
5 Biomolecule Software Market by Application
  1. 5.1 Biomolecule Software Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Research Center
  5. 5.2 Global Biomolecule Software Sales Value by Application
  6. 5.2.1 Global Biomolecule Software Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biomolecule Software Sales Value by Application (2021-2032)
  8. 5.2.3 Global Biomolecule Software Sales Value Share by Application (2021-2032)
6 Biomolecule Software Regional Value Analysis
  1. 6.1 Global Biomolecule Software Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biomolecule Software Sales Value by Region (2021-2032)
  3. 6.2.1 Global Biomolecule Software Sales Value by Region: 2021-2026
  4. 6.2.2 Global Biomolecule Software Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biomolecule Software Sales Value (2021-2032)
  7. 6.3.2 North America Biomolecule Software Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Biomolecule Software Sales Value (2021-2032)
  10. 6.4.2 Europe Biomolecule Software Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Biomolecule Software Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Biomolecule Software Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Biomolecule Software Sales Value (2021-2032)
  16. 6.6.2 South America Biomolecule Software Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Biomolecule Software Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Biomolecule Software Sales Value Share by Country, 2025 VS 2032
7 Biomolecule Software Country-level Value Analysis
  1. 7.1 Global Biomolecule Software Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biomolecule Software Sales Value by Country (2021-2032)
  3. 7.2.1 Global Biomolecule Software Sales Value by Country (2021-2026)
  4. 7.2.2 Global Biomolecule Software Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Biomolecule Software Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Biomolecule Software Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Biomolecule Software Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Biomolecule Software Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Biomolecule Software Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Biomolecule Software Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Biomolecule Software Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Biomolecule Software Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Biomolecule Software Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Biomolecule Software Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Biomolecule Software Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Biomolecule Software Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Biomolecule Software Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Biomolecule Software Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Biomolecule Software Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Biomolecule Software Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Biomolecule Software Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Biomolecule Software Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Biomolecule Software Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Biomolecule Software Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Biomolecule Software Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Biomolecule Software Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Biomolecule Software Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Biomolecule Software Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Biomolecule Software Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Biomolecule Software Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Biomolecule Software Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Biomolecule Software Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Biomolecule Software Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Biomolecule Software Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Biomolecule Software Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Hamilton Thorne
  2. 8.1.1 Hamilton Thorne Company Information
  3. 8.1.2 Hamilton Thorne Business Overview
  4. 8.1.3 Hamilton Thorne Biomolecule Software Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Hamilton Thorne Biomolecule Software Product Portfolio
  6. 8.1.5 Hamilton Thorne Recent Developments
  7. 8.2 Hermes Medical Solutions, Inc
  8. 8.2.1 Hermes Medical Solutions, Inc Company Information
  9. 8.2.2 Hermes Medical Solutions, Inc Business Overview
  10. 8.2.3 Hermes Medical Solutions, Inc Biomolecule Software Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Hermes Medical Solutions, Inc Biomolecule Software Product Portfolio
  12. 8.2.5 Hermes Medical Solutions, Inc Recent Developments
  13. 8.3 INDICAL BIOSCIENCE
  14. 8.3.1 INDICAL BIOSCIENCE Company Information
  15. 8.3.2 INDICAL BIOSCIENCE Business Overview
  16. 8.3.3 INDICAL BIOSCIENCE Biomolecule Software Revenue and Gross Margin (2021-2026)
  17. 8.3.4 INDICAL BIOSCIENCE Biomolecule Software Product Portfolio
  18. 8.3.5 INDICAL BIOSCIENCE Recent Developments
  19. 8.4 lexogen
  20. 8.4.1 lexogen Company Information
  21. 8.4.2 lexogen Business Overview
  22. 8.4.3 lexogen Biomolecule Software Revenue and Gross Margin (2021-2026)
  23. 8.4.4 lexogen Biomolecule Software Product Portfolio
  24. 8.4.5 lexogen Recent Developments
  25. 8.5 Repligen
  26. 8.5.1 Repligen Company Information
  27. 8.5.2 Repligen Business Overview
  28. 8.5.3 Repligen Biomolecule Software Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Repligen Biomolecule Software Product Portfolio
  30. 8.5.5 Repligen Recent Developments
  31. 8.6 SCC SOFT COMPUTER
  32. 8.6.1 SCC SOFT COMPUTER Company Information
  33. 8.6.2 SCC SOFT COMPUTER Business Overview
  34. 8.6.3 SCC SOFT COMPUTER Biomolecule Software Revenue and Gross Margin (2021-2026)
  35. 8.6.4 SCC SOFT COMPUTER Biomolecule Software Product Portfolio
  36. 8.6.5 SCC SOFT COMPUTER Recent Developments
  37. 8.7 Oxford Instruments
  38. 8.7.1 Oxford Instruments Company Information
  39. 8.7.2 Oxford Instruments Business Overview
  40. 8.7.3 Oxford Instruments Biomolecule Software Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Oxford Instruments Biomolecule Software Product Portfolio
  42. 8.7.5 Oxford Instruments Recent Developments
  43. 8.8 Partek, Inc.
  44. 8.8.1 Partek, Inc. Company Information
  45. 8.8.2 Partek, Inc. Business Overview
  46. 8.8.3 Partek, Inc. Biomolecule Software Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Partek, Inc. Biomolecule Software Product Portfolio
  48. 8.8.5 Partek, Inc. Recent Developments
  49. 8.9 Stilla Technologies
  50. 8.9.1 Stilla Technologies Company Information
  51. 8.9.2 Stilla Technologies Business Overview
  52. 8.9.3 Stilla Technologies Biomolecule Software Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Stilla Technologies Biomolecule Software Product Portfolio
  54. 8.9.5 Stilla Technologies Recent Developments
  55. 8.10 Vela Diagnostics
  56. 8.10.1 Vela Diagnostics Company Information
  57. 8.10.2 Vela Diagnostics Business Overview
  58. 8.10.3 Vela Diagnostics Biomolecule Software Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Vela Diagnostics Biomolecule Software Product Portfolio
  60. 8.10.5 Vela Diagnostics Recent Developments
  61. 8.11 Vittoriobasurto
  62. 8.11.1 Vittoriobasurto Company Information
  63. 8.11.2 Vittoriobasurto Business Overview
  64. 8.11.3 Vittoriobasurto Biomolecule Software Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Vittoriobasurto Biomolecule Software Product Portfolio
  66. 8.11.5 Vittoriobasurto Recent Developments
  67. 8.12 SCIEX
  68. 8.12.1 SCIEX Company Information
  69. 8.12.2 SCIEX Business Overview
  70. 8.12.3 SCIEX Biomolecule Software Revenue and Gross Margin (2021-2026)
  71. 8.12.4 SCIEX Biomolecule Software Product Portfolio
  72. 8.12.5 SCIEX Recent Developments
  73. 8.13 SoftGenetics, LLC.
  74. 8.13.1 SoftGenetics, LLC. Company Information
  75. 8.13.2 SoftGenetics, LLC. Business Overview
  76. 8.13.3 SoftGenetics, LLC. Biomolecule Software Revenue and Gross Margin (2021-2026)
  77. 8.13.4 SoftGenetics, LLC. Biomolecule Software Product Portfolio
  78. 8.13.5 SoftGenetics, LLC. Recent Developments
  79. 8.14 Benchling
  80. 8.14.1 Benchling Company Information
  81. 8.14.2 Benchling Business Overview
  82. 8.14.3 Benchling Biomolecule Software Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Benchling Biomolecule Software Product Portfolio
  84. 8.14.5 Benchling Recent Developments
  85. 8.15 BioSistemika
  86. 8.15.1 BioSistemika Company Information
  87. 8.15.2 BioSistemika Business Overview
  88. 8.15.3 BioSistemika Biomolecule Software Revenue and Gross Margin (2021-2026)
  89. 8.15.4 BioSistemika Biomolecule Software Product Portfolio
  90. 8.15.5 BioSistemika Recent Developments
  91. 8.16 CapitalBio Technology
  92. 8.16.1 CapitalBio Technology Company Information
  93. 8.16.2 CapitalBio Technology Business Overview
  94. 8.16.3 CapitalBio Technology Biomolecule Software Revenue and Gross Margin (2021-2026)
  95. 8.16.4 CapitalBio Technology Biomolecule Software Product Portfolio
  96. 8.16.5 CapitalBio Technology Recent Developments
  97. 8.17 cytena GmbH
  98. 8.17.1 cytena GmbH Company Information
  99. 8.17.2 cytena GmbH Business Overview
  100. 8.17.3 cytena GmbH Biomolecule Software Revenue and Gross Margin (2021-2026)
  101. 8.17.4 cytena GmbH Biomolecule Software Product Portfolio
  102. 8.17.5 cytena GmbH Recent Developments
  103. 8.18 Eppendorf SE
  104. 8.18.1 Eppendorf SE Company Information
  105. 8.18.2 Eppendorf SE Business Overview
  106. 8.18.3 Eppendorf SE Biomolecule Software Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Eppendorf SE Biomolecule Software Product Portfolio
  108. 8.18.5 Eppendorf SE Recent Developments
  109. 8.19 GenomSys
  110. 8.19.1 GenomSys Company Information
  111. 8.19.2 GenomSys Business Overview
  112. 8.19.3 GenomSys Biomolecule Software Revenue and Gross Margin (2021-2026)
  113. 8.19.4 GenomSys Biomolecule Software Product Portfolio
  114. 8.19.5 GenomSys Recent Developments
  115. 8.20 Mission Bio
  116. 8.20.1 Mission Bio Company Information
  117. 8.20.2 Mission Bio Business Overview
  118. 8.20.3 Mission Bio Biomolecule Software Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Mission Bio Biomolecule Software Product Portfolio
  120. 8.20.5 Mission Bio Recent Developments
  121. 8.21 Multid Analyses AB
  122. 8.21.1 Multid Analyses AB Company Information
  123. 8.21.2 Multid Analyses AB Business Overview
  124. 8.21.3 Multid Analyses AB Biomolecule Software Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Multid Analyses AB Biomolecule Software Product Portfolio
  126. 8.21.5 Multid Analyses AB Recent Developments
  127. 8.22 PhenoSystems SA
  128. 8.22.1 PhenoSystems SA Company Information
  129. 8.22.2 PhenoSystems SA Business Overview
  130. 8.22.3 PhenoSystems SA Biomolecule Software Revenue and Gross Margin (2021-2026)
  131. 8.22.4 PhenoSystems SA Biomolecule Software Product Portfolio
  132. 8.22.5 PhenoSystems SA Recent Developments
  133. 8.23 Progenie Molecular
  134. 8.23.1 Progenie Molecular Company Information
  135. 8.23.2 Progenie Molecular Business Overview
  136. 8.23.3 Progenie Molecular Biomolecule Software Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Progenie Molecular Biomolecule Software Product Portfolio
  138. 8.23.5 Progenie Molecular Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst